Navigation Links
Cerecor Announces Clearance of IND for FP01
Date:4/11/2012

BALTIMORE, April 11, 2012 /PRNewswire/ -- Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced that its Investigational New Drug (IND) Application for FP01 for the treatment of cough has cleared the 30 day deliberation period by the U.S. Food and Drug Administration (FDA).  The Company plans to immediately characterize the pharmacokinetics of FP01 lozenges in humans and thereafter to initiate an exploratory Phase II acute cough study in healthy subjects with upper respiratory tract infections (URTI). 

(Logo: http://photos.prnewswire.com/prnh/20120411/PH85852LOGO )

"Acceptance by the FDA of this application and the advancement of FP01 to clinical testing are important milestones for the Company and key steps along the path to commercialize a treatment for acute and chronic cough. The data we plan to generate from the initial Phase II study will educate us about the effect size of FP01 as an antitussive, providing for future studies," said Dr. Blake Paterson, CEO and co-founder of Cerecor.

About Cerecor Inc.

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. Cerecor's product pipeline also includes preclinical drug development candidates in cognition and schizophreniawww.cerecor.com

For More Information, contact:
John Dierkes
Kennedy Advisors
john@kennedyadvice.com
(410) 935-9334


'/>"/>
SOURCE Cerecor Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Botanic Announces Results of Annual General Meeting
2. iBio Announces Production of Biosimilar Palivizumab with its iBioLaunch™ Technology
3. SafeWire, LLC. Announces first US product launch of Y-wire™
4. Sunpeaks Ventures Announces Letter of Intent to Export Clotamin to Top Russian Pharmacies
5. Rapid Fire Marketing Announces the First Shipment of its Vapor Inhaler Model Named the CannaCig Has Passed All Patient Tests; Second Round of Production to Start This Week
6. Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores
7. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2012 Results
8. BioNeutral Group Announces Positive Results for the Ygiene 206 Sterilization Tests
9. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
10. BONESUPPORTS New CEO Announces 100 Day Plan
11. Sunpeaks Ventures Announces Agreement with Albeck Financial Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 IRIDEX Corporation (NASDAQ: IRIX ) ... of common stock, $0.01 par value (the "Offering" with such ...  The final terms of the Offering will depend on market ... can be no assurance as to whether or when the ... the net proceeds it will receive from this offering for ...
(Date:12/8/2016)... , Dec. 8, 2016  The global biosurgery market ... during the forecast period of 2016 to 2021. The ... 2021 from USD 18.21 billion in 2016. The market ... incidences of sports related injuries and spinal problems, increasing ... need of effective blood loss management. In ...
(Date:12/8/2016)... FLINT, Mich. , Dec. 8, 2016  Diplomat Pharmacy, Inc. ... as a 2016 Top Workplaces National Standard. ... . ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... are based on an employee survey administered by WorkplaceDynamics, LLC, a ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... ... Cellairis is a worldwide mobile device and computer repair franchise that is known ... Samsung Galaxy devices with premium parts and accessories. Cellairis has recently set-up for business ... customers. While customers do their shopping, Cellairis can accomplish a number of mobile device ...
(Date:12/9/2016)... ... ... An inventor from Cana, Va., wanted to fulfill the need for a ... , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. It is ... in a matter of minutes, or even seconds. The SAFETY STRAP FOR AMPUTEES is ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic Trainers’ ... during the summer of 2016. The program was made possible by a Pennsylvania ... Department of Health and Human Services Administration. The broadcast, Use Your Head: ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
Breaking Medicine News(10 mins):